Epidemiology of severe cutaneous adverse drug reactions in a University Hospital: a Five-year review

Introduction Severe cutaneous adverse drug reactions (SCAR) is seen in ≤5% of all hospitalized patients. It includes Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum (SJS/TEN), drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) and acute generalized exanthematous pustulosis (AGEP). Objectives The main objective was to determine the epidemiological characteristics of SCAR patients at a tertiary hospital from 2011-2015. Specifi cally, it aimed to determine the prevalence, demographic characteristics and clinical profi le of SCAR patients. Methods All SCAR patients from 2011-2015 were studied through a single-center, retrospective, descriptive, cross-sectional study. Results Sixty-eight SCAR cases were diagnosed from 2011-2015 with a prevalence rate of 6.25 per 10,000 people. Majority were 46-55 years old with slight female predominance. The most common SCAR was DIHS/DRESS (50%), followed by SJS/ TEN (30%) and AGEP (20%). Eight percent had previous drug reactions, 69% had co-morbidities and 90% were diagnosed clinically without biopsy. The antibiotics was the most common culprit drug category followed by allopurinol and anticonvulsants. Prompt withdrawal of culprit drug/s, supportive therapy, systemic steroids and antihistamine, topical emollients and saline compress were mainstay of treatment. Mortality rate was 4% for all SCAR categories Conclusion The epidemiology of SCAR in this study is similar to those reported in other literature. The adults were commonly involved; DIHS/DRESS was the most common SCAR with antibiotics being the most common culprit. Prompt withdrawal and supportive therapy were essential. Systemic steroid, antihistamine; topical emollients and saline compress resulted in improvement of patients. In contrast, there was lower prevalence rate with slight female predominance; and lower mortality rate even with the use of systemic steroids.

[1]  G. Papaioannou,et al.  Febuxostat hypersensitivity: another cause of DRESS syndrome in chronic kidney disease? , 2016, European annals of allergy and clinical immunology.

[2]  Jen-Yu Wang,et al.  Paracetamol-induced acute generalized exanthematous pustulosis in a 4-year-old girl , 2016 .

[3]  C-Y Cheng,et al.  Febuxostat‐associated drug reaction with eosinophilia and systemic symptoms (DRESS) , 2015, Journal of clinical pharmacy and therapeutics.

[4]  R. Colven,et al.  Approach to the Patient with a Suspected Cutaneous Adverse Drug Reaction. , 2015, The Medical clinics of North America.

[5]  M. Binitha,et al.  Severe Cutaneous Adverse Drug Reactions: A Clinicoepidemiological Study , 2015, Indian journal of dermatology.

[6]  R. Bakos,et al.  Severe cutaneous reactions to drugs in the setting of a general hospital* , 2014, Anais brasileiros de dermatologia.

[7]  S. Mallal,et al.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. , 2014, The journal of allergy and clinical immunology. In practice.

[8]  Rajesh Verma,et al.  Severe cutaneous adverse drug reactions. , 2013, Medical journal, Armed Forces India.

[9]  J. Reichenberg,et al.  A review of cutaneous drug eruptions. , 2013, Clinics in geriatric medicine.

[10]  N. Lai,et al.  An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. , 2012, Indian journal of dermatology, venereology and leprology.

[11]  M. Marotti.  Severe cutaneous adverse reactions (SCAR) syndromes. , 2012, Revista da Associacao Medica Brasileira.

[12]  D. Metze,et al.  Histopathology of drug eruptions – general criteria, common patterns, and differential diagnosis , 2001, Dermatology practical & conceptual.

[13]  L. French,et al.  Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. , 2010, The Medical clinics of North America.

[14]  R. Wolf,et al.  Severe cutaneous adverse drug reactions: who should treat, where and how?: Facts and controversies. , 2010, Clinics in dermatology.

[15]  M. Mockenhaupt,et al.  Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, Diagnostic Criteria, Genetic Predisposition , 2009 .

[16]  Amparo Hernández-Salazar,et al.  Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. , 2006, Archives of medical research.

[17]  A R Feinstein,et al.  An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. , 1979, JAMA.